What is Robocath?
Founded in 2009 by Dr. Philippe Bencteux, Robocath designs, develops, and commercializes advanced robotic systems aimed at enhancing the safety and efficacy of treating cardiovascular diseases. The company's flagship product, R-One, is a robotic platform designed for precision in coronary angioplasty procedures, optimizing safety and complementing manual interventions. With an open architecture compatible with leading cath lab devices, R-One has demonstrated strong clinical results, achieving 100% technical success in pre-clinical trials and receiving CE marking in 2019. Robocath's mission is to become a global leader in vascular robotics, extending its reach to remote treatment of vascular emergencies and ensuring equitable access to high-quality care. The company, based in Rouen, France, employs over 60 professionals dedicated to advancing medical technology.
How much funding has Robocath raised?
Robocath has raised a total of $56.3M across 3 funding rounds:
Series A
$7.6M
Series B
$5.3M
Series C
$43.4M
Series A (2017): $7.6M with participation from M Capital Advisors, Normandie Participations, Groupe Credit Agricole, Cardio Participation, and GO Capital
Series B (2019): $5.3M led by Supernova Invest, NCI, Go Capital, Normandie Participations, and M Capital
Series C (2020): $43.4M supported by MicroPort Scientific Corporation, Anaxago, TUS-Holdings, Zhejiang Silk Road Fund, and CS Group
Key Investors in Robocath
Supernova Invest
Supernova Invest is a venture capital firm focused on deeptech innovations, providing expertise and capital to high-growth startups in sectors including healthcare. They support cutting-edge technologies developed by scientists and entrepreneurs.
NCI
NCI is a significant regional private equity player that invests in business creation, development, and transfer, managing approximately 400 million euros and focusing on SMEs and startups in northwestern France.
Go Capital
GEOC (Go Capital) is a China-Israel fund that invests in Israeli high-tech companies, particularly in Life Sciences and Digital technologies, aiming to facilitate market penetration in China.
What's next for Robocath?
The substantial enterprise-level financing positions Robocath for accelerated expansion and continued innovation in the competitive medical robotics sector. With a clear trajectory from its Series A, B, and C funding rounds, the company is poised to scale its operations, further develop its technological pipeline, and broaden its market penetration across Europe, Africa, and potentially new global territories. This strategic investment is expected to fuel research and development efforts, enhance manufacturing capabilities, and support Robocath's ambition to lead the vascular robotics market, particularly in addressing critical vascular emergencies through remote treatment solutions.
See full Robocath company page
